Premium
A longitudinal observational study of a cohort of patients with relapsing–remitting multiple sclerosis treated with glatiramer acetate
Author(s) -
Debouverie M.,
Moreau T.,
Lebrun C.,
Heinzlef O.,
Brudon F.,
Msihid J.
Publication year - 2007
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2007.01964.x
Subject(s) - glatiramer acetate , medicine , expanded disability status scale , tolerability , multiple sclerosis , discontinuation , adverse effect , observational study , natalizumab , cohort , immunology
Immunomodulatory treatments for relapsing–remitting multiple sclerosis (RRMS) are not efficacious or tolerated in all patients. It is important to evaluate alternative classes of treatment in patients failing first‐line therapy. The objective of this prospective observational study was to evaluate the efficacy and safety of glatiramer acetate in patients, to whom β ‐interferons could not be administered. The study included patients with RRMS who were intolerant to or had contraindications to β ‐interferon. After initiation of glatiramer acetate treatment, follow‐up visits were made every 3 months, when data on neurologist‐ascertained relapses and disability [Expanded Disability Status Scale (EDSS) score] were collected. Tolerability was evaluated by spontaneous adverse event reporting. Overall, 205 patients were studied and 113 (55.1%) treated for at least 4 years. The proportion of patients presenting over three relapses per year decreased from 51.2% to 8.4% in the 2 years following treatment initiation. Over 5 years of treatment, mean annualized relapse rates and mean EDSS scores remained stable (0.4–0.6 relapses/year and 3.6 ± 1.8–3.3 ± 2.1 respectively). Adverse events were reported by 179 patients, leading to discontinuation of treatment in 10 patients. Patients with RRMS to whom β ‐interferons cannot be prescribed can benefit from treatment with glatiramer acetate.